SCHEDULE: BlackRock Discloses 5.03% Stake in Rapport Therapeutics

BlackRock, Inc. has reported a 5.03% beneficial ownership stake in Rapport Therapeutics Inc. common stock as of December 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 2,397,549 shares of Rapport Therapeutics Inc. common stock.
• This represents 5.03% of the total outstanding common stock of Rapport Therapeutics Inc.
• BlackRock holds sole voting power over 2,355,378 shares and sole dispositive power over 2,397,549 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Rapport Therapeutics Inc.
• The filing was made by BlackRock, Inc. as a parent holding company, with various subsidiaries contributing to the aggregate ownership, including BlackRock Investment Management, LLC, which beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant institutional ownership stake, which is generally a neutral to slightly positive signal as it indicates a major investor's position. No negative or highly positive operational news is contained within.

Positives

• BlackRock's significant stake (5.03%) could be interpreted as a vote of confidence in Rapport Therapeutics Inc. by a major institutional investor.
• The acquisition of shares is stated to be in the ordinary course of business, suggesting a passive investment rather than an activist intent.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Rapport Therapeutics Inc., likely a biotechnology or pharmaceutical company. Such investments are common for large asset managers like BlackRock, reflecting their portfolio diversification and belief in the long-term prospects of companies within the healthcare sector.

Comparison to Industry Standards

• BlackRock's 5.03% stake in Rapport Therapeutics Inc. is a standard threshold for triggering a Schedule 13G filing, indicating a significant but generally passive investment by a large institutional asset manager.
• This level of ownership is typical for diversified funds managed by BlackRock, which often hold stakes in numerous public companies across various industries, similar to other major asset managers like Vanguard or State Street.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a major institutional investor's stake, potentially influencing market perception and liquidity.
• Management: Awareness of a significant institutional holder, which may lead to engagement on corporate strategy or governance, though the filing states a passive intent.

Next Steps

• BlackRock, Inc. will continue to monitor its ownership in Rapport Therapeutics Inc.
• Further Schedule 13G/A amendments would be filed if BlackRock's beneficial ownership significantly changes (e.g., crosses 10% or drops below 5%).

Key Dates

Recommendation

This Schedule 13G filing primarily discloses BlackRock's passive beneficial ownership of 5.03% in Rapport Therapeutics Inc. It does not contain operational or financial performance data for Rapport Therapeutics Inc. that would warrant a 'buy' or 'sell' recommendation. The presence of a major institutional investor like BlackRock is generally a neutral to slightly positive indicator, suggesting the company is on their radar for long-term portfolio allocation. Without further fundamental analysis of Rapport Therapeutics Inc.'s business, a 'hold' recommendation is appropriate, acknowledging the institutional interest without implying immediate catalysts for significant price movement based solely on this filing.

Keywords

Rapport Therapeutics, BlackRock, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Investment, Beneficial Ownership